A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs TRQ 1501 (Primary)
- Indications Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Torque Therapeutics
- 20 Feb 2019 According to a Torque Therapeutics media release, first patient has been treated in this trial.
- 23 Jan 2019 Status changed from planning to recruiting.
- 29 Nov 2018 New trial record